Nomifensine: effect in Parkinsonian patients not receiving levodopa.

AUTOR(ES)

Park, D M

RESUMO

A clinical trial using the anti-depressant nomifensine in Parkinsonism is reported. Eighteen subjects not receiving levodopa participated. The drug had a small, but significant anti-Parkinsonian effect. No troublesome side effects were encountered. In the treatment of Parkinsonism, nomifensine may be considered as an alternative to amantadine or anticholinergics, especially where depression is an added feature.

Documentos Relacionados

• Ultrasensitive TSH assay and anti-parkinsonian treatment with levodopa.
• False positive diagnosis of phaeochromocytoma in a patient with Parkinson's disease receiving levodopa.
• Age influences magnitude but not duration of response to levodopa.
• Diurnal differences in response to oral levodopa.
• Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.